Lead author: Laurent Brochard, laurent.brochard@hmn.aphp.fr Three part clinical question: Patients: Intensive care unit (ICU) patients with COPD, acute dyspnoea (both infective and non-infective) and PaCO 2 >45 mm Hg. Intervention: Noninvasive bi-level airway pressure (BIPAP) ventilation (NIV) applied with or without helium (inspired oxygen fraction 0.35). Outcome: Primary -need for intubation; Secondary -duration of NIV, length of hospital stay, mortality.
Search terms: Mechanical ventilation; acute respiratory failure; COPD; endotracheal intubation.
The study: Non-blinded, concealed, randomised controlled trial with intention-to-treat analysis.
The study patients: Recruited from seven ICUs in France, Tunisia, Italy, Spain over two years.
Inclusion criteria: Patients with known or suspected COPD and acute dyspnoea, PaCO 2 >45 mm Hg (6 kPa) and two of the following factors: pH <7.35, PaCO 2 <50 mm Hg (6.67 kPa), respiratory rate >25/min. Exclusion criteria: Respiratory arrest, need for immediate intubation, pneumothorax, life expectancy <1 month, severe hypoxaemia requiring oxygen >6 L/min or FiO 2 ≥50%, inability to co-operate or fit mask, upper airway obstruction or facial trauma, haemodynamic instability (systolic pressure <80 mm Hg despite resuscitation), pregnancy. Sub-group analysis: Although intubation rates were similar between the groups, it was lower in patients who received a short NIV duration (<4 days) with helium-O 2 (18 of 57) than with air-oxygen (23 of 43, p 0.03). This suggests that any possible benefit from helium treatment may be in the early treatment stage.
Non-invasive ventilation with heliumoxygen mixture in chronic obstructive pulmonary disease
Compared to oxygen-air mixture, a helium-oxygen mixture does not confer a significant benefit in non-invasive ventilation (NIV) of chronic obstructive pulmonary disease (COPD) patients. Intubation rate, mortality rate and duration of NIV were similar for both groups.
Level of evidence: 1 + (RCT with a low risk of bias)
Appraised by: AJ Dalton shows the use of helium-O 2 is safe and at least as good as conventional NIV for patients who comply with the study criteria. 4. Did results get omitted, and why? Yes. Nine patients (three in the control group, six in the experimental group) were excluded due to protocol deviations at inclusion. However, the results were included in the intention-to-treat analysis. 5. Did they suggest areas of further research? Yes. The authors suggested further research in the use of helium-O 2 (with a better selection of patients who are most likely to benefit) in view of the subgroup showing a reduced intubation rate for those receiving short duration NIV, but they did not suggest a possible method for identifying this subgroup. Also, they suggested a study of a more continuous helium-O 2 treatment during both NIV and unassisted ventilation. 6. Did they make any recommendations based on the results and were they appropriate? No. 7. Is the study relevant to my clinical practice? Yes. This study did look at similar patients with regard to age, sex and severity of illness as present to general critical care in the UK. However it is important to note the small range of PaCO 2 levels included in the study (45-50 mm Hg, 6-6.67 kPa]) which may limit its applicability. 8. What level of evidence does this study represent? 1 + 9. What grade of recommendation can I make on this result alone? None. 10.What grade of recommendation can I make when this study is considered along with other available evidence? None. 11.Should I change my practice because of these results? No. 12.Should I audit my current practice because of these results?
Yes. If you use helium with NIV, then these results should be audited.
